Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timo Vesikari

Showing results (41-50 of 211) with videos related to

Pageof 22
Sort By:
Clinical Immunology (Orlando, Fla.)|September 24, 2018
Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigensKirsi Tamminen, Maria Malm, Timo Vesikari, et al.
Journal of Immunology Research|April 24, 2018
Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in MiceSuvi Heinimäki, Maria Malm, Timo Vesikari, et al.
Molecular Immunology|August 31, 2016
Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 proteinMaria Malm, Kirsi Tamminen, Timo Vesikari, et al.
Antiviral Research|June 24, 2018
Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4<sup>+</sup> T lymphocytes with cytotoxic potentialSuvi Heinimäki, Maria Malm, Timo Vesikari, et al.
Viral Immunology|November 16, 2018
Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse SeraMaria Malm, Kirsi Tamminen, Timo Vesikari, et al.
The Pediatric Infectious Disease Journal|June 29, 2007
Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccineTimo Vesikari, Catherine Sadzot-Delvaux, Bernard Rentier, et al.
The Pediatric Infectious Disease Journal|January 7, 2006
Burden of rotavirus disease in European Union countriesMontse Soriano-Gabarró, Jacek Mrukowicz, Timo Vesikari, et al.
The Pediatric Infectious Disease Journal|October 19, 2016
A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month ScheduleTimo Vesikari, Sven-Arne Silfverdal, Emilia Jordanov, et al.
The Journal of Infectious Diseases|June 28, 2014
High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in childrenMaria Malm, Hanni Uusi-Kerttula, Timo Vesikari, et al.
European Journal of Pediatrics|June 19, 2010
Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension StudyTimo Vesikari, Aino Karvonen, Shannon Allen Ferrante, et al.
Pageof 22

Showing results (41-50 of 211) with videos related to

Sort By:
Pageof 22
Clinical Immunology (Orlando, Fla.)|September 24, 2018
Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigensKirsi Tamminen, Maria Malm, Timo Vesikari, et al.
Journal of Immunology Research|April 24, 2018
Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in MiceSuvi Heinimäki, Maria Malm, Timo Vesikari, et al.
Molecular Immunology|August 31, 2016
Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 proteinMaria Malm, Kirsi Tamminen, Timo Vesikari, et al.
Antiviral Research|June 24, 2018
Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4<sup>+</sup> T lymphocytes with cytotoxic potentialSuvi Heinimäki, Maria Malm, Timo Vesikari, et al.
Viral Immunology|November 16, 2018
Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse SeraMaria Malm, Kirsi Tamminen, Timo Vesikari, et al.
The Pediatric Infectious Disease Journal|June 29, 2007
Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccineTimo Vesikari, Catherine Sadzot-Delvaux, Bernard Rentier, et al.
The Pediatric Infectious Disease Journal|January 7, 2006
Burden of rotavirus disease in European Union countriesMontse Soriano-Gabarró, Jacek Mrukowicz, Timo Vesikari, et al.
The Pediatric Infectious Disease Journal|October 19, 2016
A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month ScheduleTimo Vesikari, Sven-Arne Silfverdal, Emilia Jordanov, et al.
The Journal of Infectious Diseases|June 28, 2014
High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in childrenMaria Malm, Hanni Uusi-Kerttula, Timo Vesikari, et al.
European Journal of Pediatrics|June 19, 2010
Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension StudyTimo Vesikari, Aino Karvonen, Shannon Allen Ferrante, et al.
Pageof 22